SCHEMBL259103

SCHEMBL259103

Cc1cccc(NC(=O)c2ncccc2O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.58
KMT2A Q03164 6/20 0.58
MEN1 O00255 5/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
ALDH1A1 P00352 3/20 0.58
KDM4E B2RXH2 2/20 0.58
MAPT P10636 1/20 0.58
RXFP1 Q9HBX9 1/20 0.55
LMNA P02545 2/20 0.53
FLT3 P36888 2/20 0.52
MAP4K1 Q92918 1/20 0.52
HSD17B10 Q99714 1/20 0.51
KCNK3 O14649 2/20 0.51
KCNK9 Q9NPC2 2/20 0.51
KCNH2 Q12809 1/20 0.51
PKM P14618 1/20 0.51
GRM4 Q14833 3/20 0.51
CSF1R P07333 1/20 0.50
RET P07949 1/20 0.50
PDGFRB P09619 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14284356 0.88 KDM4E (0.61) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL18027788 0.84 KDM4E (0.73) SMN1; SMN2ALDH1A1KDM4EMAPTLMNA
SCHEMBL14284353 0.83 GRM4 (0.73) KMT2AMEN1SMN1; SMN2ALDH1A1MAPT
SCHEMBL13201028 0.82 ATR (0.61) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL14284355 0.80 TLR7 (0.67) KMT2AMEN1KDM4EMAPT
SCHEMBL29723905 0.78 KDR (0.72) KMT2AMEN1SMN1; SMN2ALDH1A1LMNA
SCHEMBL30643208 0.78 KDR (0.72) KMT2AMEN1SMN1; SMN2ALDH1A1LMNA
SCHEMBL259238 0.78 KDR (0.72) KMT2AMEN1SMN1; SMN2ALDH1A1LMNA
SCHEMBL14284368 0.77 MMP13 (0.60) KMT2ASMN1; SMN2ALDH1A1KDM4ERXFP1
SCHEMBL23367919 0.76 ALDH1A1 (0.64) KMT2AMEN1SMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A ELANE 4761/4885KMT2A 1722/4885MEN1 3330/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A ELANE 4761/4885KMT2A 1722/4885MEN1 3330/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A ELANE 4761/4885KMT2A 1722/4885MEN1 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.